# A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults

> **NCT02298179** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 288 (actual)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** RSV F subunit 45 μg No adjuvant
- **BIOLOGICAL:** RSV F subunit 45 μg Aluminum hydroxide adjuvant
- **BIOLOGICAL:** RSV F subunit 45 μg MF59 adjuvant
- **BIOLOGICAL:** RSV F subunit 90 μg No adjuvant
- **BIOLOGICAL:** RSV F subunit 90 μg Aluminum hydroxide adjuvant
- **BIOLOGICAL:** RSV F subunit 90 μg MF59 adjuvant
- **BIOLOGICAL:** RSV F subunit 135 μg No adjuvant
- **BIOLOGICAL:** RSV F subunit 135 μg Aluminum hydroxide adjuvant
- **BIOLOGICAL:** RSV F subunit 135 μg MF59 adjuvant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02298179
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-19
- **Primary completion:** 2017-03-27
- **Final completion:** 2017-03-27
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2018-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02298179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02298179, "A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02298179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*